HTGF | High-Tech Gruenderfonds
High-Tech Gründerfonds Management GmbH is a venture capital firm based in Bonn, Germany, specializing in early-stage investments in high-tech startups. Established in 2005, the firm focuses on technology-driven companies across various sectors, including information and communication technology, life sciences, healthcare, automation, and cleantech. HTGF typically invests in companies that have been operational for no more than one year, aiming to contribute up to €0.6 million in initial funding and up to €3 million in follow-on financing. The firm seeks a minority stake, generally around 15%, and provides a subordinated loan convertible into equity, with deferred interest for up to four years to support liquidity. With a total investment volume of approximately €895.5 million across three funds, HTGF has successfully supported over 500 startups and attracted more than €2 billion in follow-on investments from external sources. The firm's investors include notable public and private entities, underscoring its role as a key player in fostering innovation and growth within the German startup ecosystem.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Health Care
Hema.to
Seed Round in 2025
Hema.to specializes in AI-powered blood cancer detection software. It automates the analysis of flow cytometry data, enhancing lab efficiency and accuracy.
Lindis Blood Care
Venture Round in 2024
Lindis Blood Care is focused on improving the outcomes of cancer surgeries through the development of an innovative medical device that removes cancer cells from salvaged blood. This technology facilitates the possibility of self-blood administration, allowing cancer patients to receive autologous blood transfusions during their procedures. By enabling the safe use of blood collected during surgery, Lindis Blood Care aims to enhance the recovery process and overall well-being of patients undergoing cancer treatment.
Aignostics
Series B in 2024
Founded in 2018, Aignostics develops AI-powered diagnostics and pathology software solutions for pharmaceutical research and clinical applications. Its explainable AI overcomes the limitations of conventional 'black-box' AI by providing precise heatmaps and image overlays, enabling pathologists to verify results quickly.
CustomSurg
Seed Round in 2024
CustomSurg is a company focused on enhancing the treatment of complex bone fractures, particularly those involving joints. It develops fracture-specific bone plates that are tailored to match the unique anatomy of individual patients using advanced technologies such as computer tomography and 3D printing. This personalized approach provides improved stability for bone repairs, which can significantly reduce surgery time and lower long-term healthcare costs for patients. By offering a software solution for optimized surgical planning and designing patient-specific implants and instruments, CustomSurg shifts the treatment strategy from a subjective to an objective framework, aiming to improve outcomes for approximately 400,000 trauma patients in a market valued at $1.2 billion. The involvement of a Harvard Medical School surgeon in directing the medical aspects of the company adds a layer of credibility to its innovative offerings.
Kranus Health
Series A in 2023
Kranus Health is a global leader in virtual care for urology. It focuses on developing and providing clinically validated therapies for various urological conditions, ranging from andrology to uro-oncology.
Hema.to
Seed Round in 2023
Hema.to specializes in AI-powered blood cancer detection software. It automates the analysis of flow cytometry data, enhancing lab efficiency and accuracy.
hbox
Seed Round in 2023
HBOX Therapies is a developer of technology that facilitates the lung-protective treatment of respiratory patients. They produce miniaturized hyperoxygenation therapies. The technology's application is miniature respiratory assistance for patients suffering from lung failure.
PraxisEins.
Pre Seed Round in 2023
PraxisEins is a healthcare startup focused on enhancing outpatient care through innovative technology. The company develops a software-enabled platform that assists physicians in digitizing their processes, ultimately aimed at improving patient care and alleviating administrative burdens. By leveraging modern technology, PraxisEins enables doctors to conduct same-day consultations with patients, addressing the supply vacuum in outpatient services. Through its solutions, the company seeks to streamline workflows for healthcare providers and enhance the overall efficiency of outpatient care.
Aignostics
Series A in 2022
Founded in 2018, Aignostics develops AI-powered diagnostics and pathology software solutions for pharmaceutical research and clinical applications. Its explainable AI overcomes the limitations of conventional 'black-box' AI by providing precise heatmaps and image overlays, enabling pathologists to verify results quickly.
Kranus Health
Series A in 2022
Kranus Health is a global leader in virtual care for urology. It focuses on developing and providing clinically validated therapies for various urological conditions, ranging from andrology to uro-oncology.
Lindis Blood Care
Venture Round in 2022
Lindis Blood Care is focused on improving the outcomes of cancer surgeries through the development of an innovative medical device that removes cancer cells from salvaged blood. This technology facilitates the possibility of self-blood administration, allowing cancer patients to receive autologous blood transfusions during their procedures. By enabling the safe use of blood collected during surgery, Lindis Blood Care aims to enhance the recovery process and overall well-being of patients undergoing cancer treatment.
Emergence Therapeutics
Series A in 2021
Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing innovative antibody-drug conjugates (ADCs) to address high-need cancers. Established in 2019, the company leverages advanced technologies in antibody design, linker systems, and therapeutic payloads to create targeted treatments. Its lead program specifically targets Nectin-4, a clinically validated marker for various cancers, utilizing a highly specific antibody in combination with optimized linker technology and amanitin as the payload. This approach aims to provide effective therapeutic options for challenging cancer types. Emergence Therapeutics is also exploring opportunities to develop additional first- or best-in-class ADCs to meet unmet medical needs in oncology.
Abalos Therapeutics
Series A in 2021
Abalos Therapeutics GmbH is a biotechnology company based in Essen, Germany, focused on the development of immuno-oncology therapeutics. Established in 2019, the company specializes in creating arenavirus-based drug candidates aimed at activating immune responses against cancerous tumors and metastases. Utilizing its proprietary Fast Evolution platform, Abalos Therapeutics generates virus strains with optimized anti-tumoral properties. The company's innovative approach to virotherapy seeks to harness the immune stimulation capabilities of arenaviruses, enabling the immune system to specifically target and eliminate malignant tumor tissue. Through its advanced therapeutic candidates, Abalos Therapeutics aims to provide new treatment options for cancer patients.
Cardior Pharmaceuticals
Series B in 2021
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.
Kranus Health
Seed Round in 2021
Kranus Health is a global leader in virtual care for urology. It focuses on developing and providing clinically validated therapies for various urological conditions, ranging from andrology to uro-oncology.
Aignostics
Seed Round in 2020
Founded in 2018, Aignostics develops AI-powered diagnostics and pathology software solutions for pharmaceutical research and clinical applications. Its explainable AI overcomes the limitations of conventional 'black-box' AI by providing precise heatmaps and image overlays, enabling pathologists to verify results quickly.
iATROS
Seed Round in 2020
iATROS GmbH is a Munich-based company founded in 2019 that specializes in developing a mobile application and platform aimed at enhancing the care of cardiology patients. The platform connects patients with medical caregivers and offers a range of services, including therapy and medication planning, progress tracking, ECG diagnosis, and the maintenance of blood pressure and sugar databases. It also facilitates consultations with physicians and enables the secure storage of health data. As the prevalence of cardiovascular diseases increases, iATROS aims to improve the lives of both chronic and acute patients while addressing the significant healthcare costs associated with these conditions. By leveraging smart health trackers, vital data collection, and advanced AI analytics, the company enhances treatment outcomes and provides patients with 24/7 access to healthcare professionals, ensuring they feel safe in managing their conditions.
Lindis Blood Care
Venture Round in 2019
Lindis Blood Care is focused on improving the outcomes of cancer surgeries through the development of an innovative medical device that removes cancer cells from salvaged blood. This technology facilitates the possibility of self-blood administration, allowing cancer patients to receive autologous blood transfusions during their procedures. By enabling the safe use of blood collected during surgery, Lindis Blood Care aims to enhance the recovery process and overall well-being of patients undergoing cancer treatment.
Abalos Therapeutics
Series A in 2019
Abalos Therapeutics GmbH is a biotechnology company based in Essen, Germany, focused on the development of immuno-oncology therapeutics. Established in 2019, the company specializes in creating arenavirus-based drug candidates aimed at activating immune responses against cancerous tumors and metastases. Utilizing its proprietary Fast Evolution platform, Abalos Therapeutics generates virus strains with optimized anti-tumoral properties. The company's innovative approach to virotherapy seeks to harness the immune stimulation capabilities of arenaviruses, enabling the immune system to specifically target and eliminate malignant tumor tissue. Through its advanced therapeutic candidates, Abalos Therapeutics aims to provide new treatment options for cancer patients.
Cardior Pharmaceuticals
Series A in 2017
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.
PERORA
Seed Round in 2013
PERORA GmbH is a biotechnology company based in Heidelberg, Germany, that focuses on developing innovative solutions for weight management and obesity treatment. Established in 2013, the company has created a polymer-based fat-binding medical device and has also produced REDIA, a nutritional supplement that is clinically validated for lowering postprandial blood sugar levels in type 2 diabetes patients. REDIA is the first supplement with a health claim approved in the European Union and the United States, and the company holds patents for this product in multiple countries. PERORA is strategically positioning itself to build a subscription-based business model for self-management of chronic age-related metabolic health within Europe, with plans to expand its licensing efforts internationally.
Public Health Solutions
Venture Round in 2008
Public Health Solutions they provide services that improve the health of low-income, and high-risk families, and communities.
HAPILA
Seed Round in 2008
HAPILA GmbH, founded in 2007 and based in Gera, Germany, specializes in pharmaceutical and chemical development services. The company focuses on the purification and processing of active pharmaceutical ingredients, providing solutions that encompass process development, analytical method development, and regulatory affairs consultancy. HAPILA’s services include quality control of raw materials, drug substances, and intermediates; cleaning validation; and the certification of reference standard substances. It also engages in the research, development, and manufacture of sophisticated active pharmaceutical ingredients, catering primarily to the pharmaceutical and biotech sectors. The company prides itself on flexibility and ethical business practices, fostering trust and cooperation with clients through open communication. As an independent enterprise, HAPILA is committed to continuous growth in its personnel and technological capabilities to enhance its development and manufacturing capacities.
Public Health Solutions
Series A in 2006
Public Health Solutions they provide services that improve the health of low-income, and high-risk families, and communities.
Medical Decision Alliance
Medical Decision Alliance operates a healthcare start-up. Medical Decision Alliance builds the key reference database for surgery.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.